Triple Negative Breast Cancer News and Research

RSS

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

The I-SPY 2 TRIAL, a randomized phase II clinical trial for breast cancer launched through a unique partnership with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and sponsored by QuantumLeap Healthcare Collaborative has graduated the first two drugs from its innovative, multidrug standing platform trial.

27 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Researchers test promising new breast cancer drugs

The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.

14 Dec 2013

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

VG Life Sciences, a biotechnology company, announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.

13 Dec 2013

Researchers find way to stop first part of breast cancer metastasis in mice

Cell biologists at Johns Hopkins have identified a unique class of breast cancer cells that lead the process of invasion into surrounding tissues. Because invasion is the first step in the deadly process of cancer metastasis, the researchers say they may have found a weak link in cancer's armor and a possible new target for therapy.

13 Dec 2013

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

HSET protein could help doctors identify aggressive breast cancers in African-American patients

African-American women who get breast cancer often get more aggressive forms of the disease and at younger ages than other women.

12 Dec 2013

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment.

12 Dec 2013

Increased levels of protein HSET linked with worse breast cancer outcomes in African-Americans

Among African-American women with breast cancer, increased levels of the protein HSET were associated with worse breast cancer outcomes, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

Researcher receives $225,000 grant to study epigenetic changes associated with chemotherapy

Western University cancer researcher Shun-Cheng (Shawn) Li, PhD, has been awarded a China-Canada Joint Health Research Initiative grant from the Canadian Institutes of Health Research (CIHR).

26 Nov 2013

MIT researchers design stealth drug delivery system to attack TNBC cells

Some of the most dangerous cancers are those that can outmaneuver the very drugs designed to defeat them, but researchers are now reporting a new Trojan-horse approach. In a preliminary study in the journal ACS Nano focusing on a type of breast cancer that is highly resistant to current therapies, they describe a way to sneak small particles into tumor cells, lower their defenses and attack them with drugs, potentially making the therapy much more effective.

25 Oct 2013

"One-two punch" disables tumors' defenses

An aggressive form of breast cancer known as "triple negative" is very difficult to treat: Chemotherapy can shrink such tumors for a while, but in many patients they grow back and gain resistance to the original drugs.

25 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).

21 Oct 2013

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.

15 Oct 2013

Women of Mexican descent more likely to be diagnosed with aggressive form of breast cancer

Scientific data suggest that a woman reduces her risk of breast cancer by breastfeeding, having multiple children and giving birth at a younger age. A study led by the University of California, San Diego School of Medicine and recently published online by Cancer Epidemiology, Biomarkers & Prevention, indicates that women of Mexican descent may not fit that profile. In fact, results suggest that women of Mexican descent with more children and those who breastfeed are more likely to be diagnosed with an aggressive form of breast cancer.

2 Oct 2013

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen.

21 Sep 2013

Researchers identify the way FMRP contributes to progression of breast cancer

A research team led by scientists from VIB/KU Leuven, Belgium, and the University of Rome Tor Vergata, Italy, in collaboration with several research centers and hospitals in Italy, the United Kingdom and, Belgium, has identified the way Fragile X Mental Retardation Protein or FMRP contributes to the progression of breast cancer.

18 Sep 2013

Cleveland Clinic creates spin-off company to develop vaccine for preventing breast cancer

Cleveland Clinic Innovations has created a spin-off company to develop a preventive breast cancer vaccine based on research from Cleveland Clinic's Lerner Research Institute.

18 Sep 2013

Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor's ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center report today in Nature Communications.

12 Sep 2013

Triple Negative Breast Cancer News and Research

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Researchers test promising new breast cancer drugs

VG Life Sciences provides update to HCQ-sorafenib combination Phase I Study for advanced stage solid tumors

Researchers find way to stop first part of breast cancer metastasis in mice

New treatment needed for women with HER2- and hormone receptor-positive breast cancer with PIK3CA mutation

HSET protein could help doctors identify aggressive breast cancers in African-American patients

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

Increased levels of protein HSET linked with worse breast cancer outcomes in African-Americans

Researcher receives $225,000 grant to study epigenetic changes associated with chemotherapy

MIT researchers design stealth drug delivery system to attack TNBC cells

"One-two punch" disables tumors' defenses

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Women of Mexican descent more likely to be diagnosed with aggressive form of breast cancer

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

Researchers identify the way FMRP contributes to progression of breast cancer

Cleveland Clinic creates spin-off company to develop vaccine for preventing breast cancer

Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News